Home › Clear-cell metastatic renal cell carcinoma › Texas › Houston
Clear-cell metastatic renal cell carcinoma clinical trials in Houston, TX
3 studies for Clear-cell metastatic renal cell carcinoma are looking for participants at sites in and around Houston (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
RecruitingPhase 1
- NEO-811 Houston Site, Houston
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
RecruitingPhase 1/2
- Texas Oncology - Gulf Coast, Houston
- University of Texas MD Anderson Cancer Center, Houston
- Texas Oncology - Gulf Coast, Houston
- and 1 more
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
RecruitingPhase 3
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
Clear-cell metastatic renal cell carcinoma trials in other cities
- Baldwin Park, CA7 studies
- New York City, NY5 studies
- Dallas, TX5 studies
- Nashville, TN5 studies
- Rochester, MN4 studies
- Cleveland, OH4 studies
- Waukegan, IL4 studies
- St. Louis, MO4 studies
- Ann Arbor, MI3 studies
- San Francisco, CA3 studies
- San Diego, CA3 studies
- Omaha, NE3 studies
Other studies in Houston
- Non-Small Cell Lung Cancer145 studies
- Breast Cancer126 studies
- Cancer (all types)121 studies
- Metastatic Cancer104 studies
- Colorectal Cancer102 studies
- Ovarian Cancer89 studies
- Acute Myeloid Leukemia85 studies
- Lung Cancer78 studies
- Prostate Cancer76 studies
- Endometrial Cancer68 studies
- Pancreatic Cancer61 studies
- Melanoma59 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.